CRGX CARGO Therapeutics
- 17.695
- +0.465+2.70%
CARGO Therapeutics News
Cargo Therapeutics Draws Bullish View at William Blair on Lead Asset
William Blair Initiates Coverage On Cargo Therapeutics With Outperform Rating
William Blair Initiates CARGO Therapeutics(CRGX.US) With Buy Rating
H.C. Wainwright Maintains CARGO Therapeutics(CRGX.US) With Buy Rating, Maintains Target Price $33
Promising Outlook for Cargo Therapeutics: Buy Rating Backed by Strong Financials and Clinical Developments
Truist Financial Maintains CARGO Therapeutics(CRGX.US) With Buy Rating, Maintains Target Price $32
CARGO Therapeutics Advances in Cancer Therapy Development
Chardan Capital Maintains CARGO Therapeutics(CRGX.US) With Buy Rating, Maintains Target Price $28
Express News | Chardan Capital Maintains Buy on Cargo Therapeutics, Maintains $28 Price Target
Cargo Therapeutics Analyst Ratings
Cargo Therapeutics Reports Q3 EPS (88c) Consensus ($1.13)
CARGO Therapeutics: Anup Radhakrishnan, CFO of CARGO Therapeutics, Appointed as COO and CFO >CRGX
CARGO Therapeutics | 10-Q: Q3 2024 Earnings Report
Express News | CARGO Therapeutics Inc: Qtrly Shr Loss $0.88
Express News | CARGO Therapeutics Inc: Extending Cash Runway Through 2026
CARGO Therapeutics | 8-K: CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Press Release: CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Express News | CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
CARGO Therapeutics to Participate in Upcoming Investor Conferences
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity
Analysis
Price Target
No Data
No Data